{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:11:22Z","timestamp":1769238682619,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,15]],"date-time":"2006-03-15T00:00:00Z","timestamp":1142380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The whole-blood interferon-gamma release assay (IGRA) is recommended in some settings as an alternative to the tuberculin skin test (TST). Outcomes from field implementation of the IGRA for routine tuberculosis (TB) testing have not been reported. We evaluated feasibility, acceptability, and costs after 1.5 years of IGRA use in San Francisco under routine program conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients seen at six community clinics serving homeless, immigrant, or injection-drug user (IDU) populations were routinely offered IGRA (Quantiferon-TB). Per guidelines, we excluded patients who were &lt;17 years old, HIV-infected, immunocompromised, or pregnant. We reviewed medical records for IGRA results and completion of medical evaluation for TB, and at two clinics reviewed TB screening logs for instances of IGRA refusal or phlebotomy failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between November 1, 2003 and February 28, 2005, 4143 persons were evaluated by IGRA. 225(5%) specimens were not tested, and 89 (2%) were IGRA-indeterminate. Positive or negative IGRA results were available for 3829 (92%). Of 819 patients with positive IGRA results, 524 (64%) completed diagnostic evaluation within 30 days of their IGRA test date. Among 503 patients eligible for IGRA testing at two clinics, phlebotomy was refused by 33 (7%) and failed in 40 (8%). Including phlebotomy, laboratory, and personnel costs, IGRA use cost $33.67 per patient tested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IGRA implementation in a routine TB control program setting was feasible and acceptable among homeless, IDU, and immigrant patients in San Francisco, with results more frequently available than the historically described performance of TST. Laboratory-based diagnosis and surveillance for <jats:italic>M. tuberculosis<\/jats:italic> infection is now possible.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-6-47","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T12:46:19Z","timestamp":1144327579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay"],"prefix":"10.1186","volume":"6","author":[{"given":"Puneet Kumar","family":"Dewan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Grinsdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Liska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fallstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L Masae","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,15]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","volume":"17","author":"RE Huebner","year":"1993","unstructured":"Huebner RE, Schein MF, Bass JBJ: The tuberculin skin test. Clin Infect Dis. 1993, 17: 968-975.","journal-title":"Clin Infect Dis"},{"key":"311_CR2","doi-asserted-by":"crossref","unstructured":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. 2000, 161: 1376-1395.","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"311_CR3","first-page":"15","volume":"52","author":"GH Mazurek","year":"2003","unstructured":"Mazurek GH, Villarino ME: Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003, 52: 15-18.","journal-title":"MMWR Recomm Rep"},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","volume":"286","author":"GH Mazurek","year":"2001","unstructured":"Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, Iademarco MF, Rothel JS: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. Jama. 2001, 286: 1740-1747. 10.1001\/jama.286.14.1740.","journal-title":"Jama"},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tube.2004.06.003","volume":"85","author":"WJ Britton","year":"2005","unstructured":"Britton WJ, Gilbert GL, Wheatley J, Leslie D, Rothel JS, Jones SL, Bradley P: Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. Tuberculosis (Edinb). 2005, 85: 137-145. 10.1016\/j.tube.2004.06.003.","journal-title":"Tuberculosis (Edinb)"},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0196-6553(02)48240-5","volume":"31","author":"A Fietta","year":"2003","unstructured":"Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, Mangiarotti P, Casali L: Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control. 2003, 31: 347-353. 10.1016\/S0196-6553(02)48240-5.","journal-title":"Am J Infect Control"},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1128\/CDLI.11.6.1089-1093.2004","volume":"11","author":"EW Taggart","year":"2004","unstructured":"Taggart EW, Hill HR, Ruegner RG, Martins TB, Litwin CM: Evaluation of an in vitro assay for gamma interferon production in response to Mycobacterium tuberculosis infections. Clin Diagn Lab Immunol. 2004, 11: 1089-1093. 10.1128\/CDLI.11.6.1089-1093.2004.","journal-title":"Clin Diagn Lab Immunol"},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1164\/rccm.200502-196OC","volume":"172","author":"G Ferrara","year":"2005","unstructured":"Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L: Routine Hospital Use of a New Commercial Whole Blood Interferon-{gamma} Assay for the Diagnosis of Tuberculosis Infection. Am J Respir Crit Care Med. 2005, 172: 631-635. 10.1164\/rccm.200502-196OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"311_CR9","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000, 49: 1-51."},{"key":"311_CR10","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000, 161: S221-47.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"311_CR11","unstructured":"Quantiferon-TB Package Insert. Cellestis International. [http:\/\/www.cellestis.com]"},{"key":"311_CR12","unstructured":"Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1997, 46: 1-55."},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","volume":"4","author":"M Pai","year":"2004","unstructured":"Pai M, Riley LW, Colford JMJ: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004, 4: 761-776. 10.1016\/S1473-3099(04)01206-X.","journal-title":"Lancet Infect Dis"},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jurban\/79.1.113","volume":"79","author":"ED Riley","year":"2002","unstructured":"Riley ED, Vlahov D, Huettner S, Beilenson P, Bonds M, Chaisson RE: Characteristics of injection drug users who utilize tuberculosis services at sites of the Baltimore city needle exchange program. J Urban Health. 2002, 79: 113-127.","journal-title":"J Urban Health"},{"key":"311_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2105\/AJPH.88.5.792","volume":"88","author":"CK Malotte","year":"1998","unstructured":"Malotte CK, Rhodes F, Mais KE: Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998, 88: 792-796.","journal-title":"Am J Public Health"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","volume":"159","author":"NN Bock","year":"1999","unstructured":"Bock NN, Metzger BS, Tapia JR, Blumberg HM: A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999, 159: 295-300.","journal-title":"Am J Respir Crit Care Med"},{"key":"311_CR17","unstructured":"Center for Medicare and Medicaid Services. Part B Extract and Summary System (BESS). CPT Code 86580. 2003, Washington D.C."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-6-47\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:28:58Z","timestamp":1630448938000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-6-47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-6-47","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]},"assertion":[{"value":"16 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"47"}}